Literature DB >> 28395234

Reirradiation for locally recurrent breast cancer.

Gustavo Nader Marta1, Tarek Hijal2, Heloisa de Andrade Carvalho3.   

Abstract

The aim of this study is to review the current status of reirradiation therapy (Re-RT) for locally recurrent breast cancer. The overall outcome of breast/chest wall Re-RT is difficult to assess because of the wide range of different treatments that a patient may have undergone and the patient's individual features. The local control and complete response rates were reported to be 43-96% and 41-71%, respectively. The combination of Re-RT and hyperthermia seems to be related to improved outcomes. Toxicity rates vary between studies, and Re-RT is generally well tolerated. Re-RT may be considered an option for patients with breast cancer relapse after prior irradiation. Further studies are needed to determine the best irradiation volume and treatment modality for patients with locally recurrent disease.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Radiation therapy; Recurrence; Reirradiation; Treatment

Mesh:

Year:  2017        PMID: 28395234     DOI: 10.1016/j.breast.2017.03.008

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  7 in total

1.  Local recurrence of breast cancer: conventionally fractionated partial external beam re-irradiation with curative intention.

Authors:  S Janssen; D Rades; A Meyer; F B Fahlbusch; I Wildfang; A Meier; S Schild; H Christiansen; C Henkenberens
Journal:  Strahlenther Onkol       Date:  2018-05-23       Impact factor: 3.621

2.  High-dose-rate Brachytherapy as Adjuvant Local rEirradiation for Salvage Treatment of Recurrent breAst cancer (BALESTRA): a retrospective mono-institutional study.

Authors:  Andrea Vavassori; Giulia Riva; Iacopo Cavallo; Ruggero Spoto; Samantha Dicuonzo; Cristiana Fodor; Stefania Comi; Raffaella Cambria; Federica Cattani; Anna Morra; Maria Cristina Leonardi; Roberta Lazzari; Mattia Intra; Alberto Luini; Viviana Enrica Galimberti; Paolo Veronesi; Roberto Orecchia; Barbara Alicja Jereczek-Fossa
Journal:  J Contemp Brachytherapy       Date:  2020-06-30

3.  Fulvestrant May Falsely Increase 17β-Estradiol Levels in Immunoassays: A Case Report of a 57-Year-Old Postmenopausal Patient With Recurrent Estrogen Receptor-Positive Breast Cancer.

Authors:  Jingxian Ding; Yali Cao; Yonghong Guo
Journal:  Front Oncol       Date:  2022-04-13       Impact factor: 5.738

4.  A Successful Therapeutic Challenge: Local Reirradiation of Breast Cancer with a Single Dose of 18 Gy Intraoperative Radiation Therapy (IORT).

Authors:  Elisabetta Bonzano; Marina Guenzi; Renzo Corvò
Journal:  Cureus       Date:  2017-06-20

Review 5.  Cancer risk assessment in modern radiotherapy workflow with medical big data.

Authors:  Fu Jin; Huan-Li Luo; Juan Zhou; Ya-Nan He; Xian-Feng Liu; Ming-Song Zhong; Han Yang; Chao Li; Qi-Cheng Li; Xia Huang; Xiu-Mei Tian; Da Qiu; Guang-Lei He; Li Yin; Ying Wang
Journal:  Cancer Manag Res       Date:  2018-06-22       Impact factor: 3.989

6.  Combined wIRA-Hyperthermia and Hypofractionated Re-Irradiation in the Treatment of Locally Recurrent Breast Cancer: Evaluation of Therapeutic Outcome Based on a Novel Size Classification.

Authors:  Markus Notter; Andreas R Thomsen; Mirko Nitsche; Robert M Hermann; Hendrik A Wolff; Gregor Habl; Karin Münch; Anca-L Grosu; Peter Vaupel
Journal:  Cancers (Basel)       Date:  2020-03-06       Impact factor: 6.639

7.  Concomitant fulvestrant with reirradiation for unresectable locoregional recurrent estrogen receptor positive (ER+) breast cancer: A case report and narrative review.

Authors:  Jingxian Ding; Yonghong Guo; Xiaoliu Jiang; Kai Li; Wenbing Fu; Yali Cao
Journal:  Medicine (Baltimore)       Date:  2020-07-24       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.